Natalizumab discontinuation: An increasingly tricky proposition

European Journal of Neurology

Volumn 19, Issue 5, 2012, Pages 663-664

  West, T W ^b,c   Killestein, J ^a   Fox, R J ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Lou Ruvo Center for Brain Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GLATIRAMER; INTERFERON; METHYLPREDNISOLONE; NATALIZUMAB;

DISEASE ACTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RELAPSE; RISK BENEFIT ANALYSIS; RISK REDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84859849594     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03574.x     Document Type: Editorial

References (10)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. TYSABRI PML safety update. 2011. (accessed 08/07/2011).
3. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758.
4. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009; 8: 28-31.
5. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68: 186-191.
6. Lenhard T, Biller A, Mueller W, Metz I, Schonberger J, Wildemann B. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 2010; 75: 831-833.
7. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-1865.
8. Berger JR, Centonze D, Comi G, et al. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol 2010; 68: 409-411.
9. Borriello G. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012; 19: 783-787.
10. Magraner MJ, Coret F, Navarre A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011; 258: 1805-1811.